Collin Moshman is a professional poker player with an honors degree in mathematics from the California Institute of Technology. He is the author of best-selling poker books Sit 'N Go Strategy and The Math of Holdem.
Collin invests in statistically undervalued microcaps, focusing particularly on the international markets. He looks for strong balance sheets, insider buying, and simple investment theses.
Avid value-focused investor who attempts to view the investment world from a perspective other than the general market opinion. I find the best way to do this is to learn and take the best ideas from history and apply them to my investment framework today.
Formerly of the buy side now an aspiring beet and raspberry farmer. Soon to be expired CFA Charterholder. I like long walks through the aisles of Aldi, dark roast coffee from Tim Horton's, and climbing mountains on two wheels.
The posts are meant to be informative and hopefully insightful. I write to share my ideas, highlight some interesting stories and to interact with other investors - please feel free to contact me if you'd like to chat further.
I make lot's of mistakes so please do your own due diligence. I don't intend to aggressively promote stocks but it's fair to say I am often talking my own book.
Don't entirely like the monetary system in the US - Quote: "It is well enough that people of our American nation do not understand our banking and monetary system, for if they did, I believe there would be a revolution before tomorrow morning."
Disclaimer: My articles and comments do not contain investment recommendations or personal investment advice to any specific person for any particular purpose. Any article or comment is not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action. Do your own research or obtain suitable personal advice. You are responsible for your own investment decisions. Any information I publish is not a recommendation or solicitation to buy or sell securities, nor am I a registered investment advisor. Investing carries risk of loss and is not suitable for all individuals.
ValueWalk has gained popularity among all circles for its breaking stories on hedge funds, and investigative reports on investments by major funds.
NOTE we do not read comments or direct messages - please contact us via email if this is important
I am an activist investor in US and Chinese stocks. I was previously an investment banker in New York Hong Kong and London for 9 years, focused on Equity Capital Markets. I look at both long ideas and short ideas and typically focus on a small number on names where I can spend the time to conduct very deep research. I spend my time living between Los Angeles and Beijing, China.
A blog about value investing, mostly in UK, Irish and US listed stocks. Interested in individual company stocks, investment funds, risk arbitrage, event driven/special situations, fixed income & even some natural resource stocks.
In addition to his ownership of the Dallas Mavericks basketball team, Cuban is an active investor in leading and cutting-edge technologies and continues to be a sought-after speaker.
Prior to his purchase of the Mavericks, Cuban co-founded Broadcast.com, the leading provider of multimedia and streaming on the Internet, in 1995, selling it to Yahoo! in July of 1999. Before Broadcast.com, Cuban co-founded MicroSolutions, a leading National Systems Integrator, in 1983, and later sold it to CompuServe.
Note: Mr. Cuban is not an active contributor to Seeking Alpha; rather, SA editors excerpt regularly from Mr. Cuban's public commentary.
John Huber is the portfolio manager of Saber Capital Management, LLC, an investment firm that manages separate accounts for clients. Saber employs a value investing strategy with a primary goal of patiently compounding capital for the long-term.
John also writes about investing at the blog www.basehitinvesting.com, and can be reached at email@example.com.
I'm an independent equity researcher, writer and investor based in Amsterdam. My primary focus is on the micro-cap segment of the market. I also work for pension funds as a member of the Board and Investment Committee. Lastly, I enjoy soccer, sports in general and brewing the best coffee one can make at home.
I am an "extreme value" investor, focusing mostly on micro and nanocap companies selling for a steep discount to price/book, price/sales, EV/EBITDA and other traditional measures of value. (Price-to-book is my favorite.) My emphasis is on low priced stocks, since the marketplace is very inefficient in valuing them. I am a dyed-in-the-wool contrarian, and like to invest in the most unloved and out of favor sectors of the market, and numerically screen for the best relative values in those out of favor sectors. I like to buy companies where the insiders are buying in the open market, to "confirm" the underlying value proposition. I like to buy stocks trading near a multiyear low, and average down aggressively if the stock moves against me (assuming the circumstances for my purchase haven't changed.) I also like special situations, including selective leveraged turnaround situations, that I can catch at their "inflection" point. I have achieved outsized annualized returns, over the last 25 years, with these strategies. I also take 5%+ positions in companies, and engage in selective shareholder activism, to hold accountable the insular and/or corrupt boards that are sadly all too common, especially in smaller, "family run" public companies.
Tal Davidson, MBA
am the a research-driven value investor. I practice deep value investing, based on the principles taught by Benjamin Graham, and practiced by Walter Schloss. Over more than a decade of performing fundamental security analysis and practicing value investing, I have refined my methods for sourcing investment ideas, performing analysis and managing a portfolio.
Read more at taldavidson.com
I am interested in small capitalized companies with a high optionality to the upside compared to the relative downside risk. I am grounded in a value based approach but will also explore special situations. I am a trained CPA and continue to practice in industry.
Warning: my twitter account is very random but will have a lot of economic and business items sprinkled with Green Bay Packer comments.
Value investor focused on micro-caps.
I write for CompleteBankData and am also a
Passively looking for a job on the buyside.
Always looking for more opportunities and to grow my professional network. Feel free to message me anytime.
Disclaimer: Nick reminds investors to always due their own due diligence on any investment, and to consult their own financial adviser or representative when necessary. Any material provided is intended as general information only, and should not be considered or relied upon as a formal investment recommendation
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
The Clinically Sound Investor is a pharmacist for a large retail corporation, with a PharmD and a BA in psychology. Fascinated by watching the rise of Walmart and Apple after 2008, he now follows the advice "know thyself" and puts expertise of understaning scientific literature to research biotechnology stocks. His investments early on were driven by binary events such as FDA Advisory Committee meetings and PDUFA dates (approvals). Despite initial successes, there were too few of these events, so he expanded into predicting Phase II/III trial results.
His writings should not be considered financial advice or the basis for investment decisions. While his interpretations of clinical trial results--which may be overlooked or even thoroughly misunderstood by Wall Street--could be helpful, they're only as good as the original reports they come from. Although written by scientists and doctors, there will always be a slant from the sponsoring company, or worse (like, say, missing data...).
Lowenthal Capital Partners (LCP) has joined Arrow Loop Research to deliver a value-based investing newsletter called Arrow Loop Research's Actionable Ideas for Maximizing Returns. Sign up for a free trial here.
LCP is operated by Trevor Lowenthal. Trevor graduated with a BA in Political Science from University of California, Davis with Summa Cum Laude distinction. Trevor is finishing his J.D. at the University of Colorado Boulder Law School.
Arrow Loop Research formed as a partnership between LCP, Dr. Paul Price, and Market Shadows (Paul is a managing partner of Market Shadows.)
Paul writes about stocks, options and the market every weekday on Real Money Pro, a subscription site on TheStreet.com. Paul has been a speaker at the International Traders Expo in New York City and the Options and Forex Expo in Las Vegas. He also gives investment seminars for subscribers of TheStreet's multiple subscription sites. Dr. Price is a featured contributor on Market Shadows.com, GuruFocus.com and TalkMarkets.com.
Paul followed his passion for the stock market when he gave up his career as a dentist to join Merrill Lynch back in April of 1987. Paul feels that he is “living the dream” of many investors. He stopped “going to work” when he turned 50 (in the year 2000) and has been living well from his investment returns ever since.
Paul enjoys sharing the accumulated market wisdom he’s gained from years in the markets. He loves analyzing companies and picking individual stocks. According to Paul, once you know what equities to buy, option writing (selling covered calls and/or naked puts) just flows naturally. They serve as ways to impose investment discipline and create income while providing an extra margin of safety versus plain vanilla share ownership. Paul’s articles stand out for their unique graphics which are packed with information which distills our TMI (too much information) world into easy to understand, and actionable advice.
I am an Senior Biotech Analyst with Zacks Investment Research, Inc. I joined Zacks in February 2014.
Prior to joining Zacks, I was an NRSA Postdoctoral Fellow working in a cancer genetics laboratory.
I received my PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill. I also have my BS and MS in Biochemistry from Virginia Tech.
Over 30 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
Nisha Hirani, M.D. is an experienced healthcare professional who serves as the Chief Scientific Advisor for Berg Capital Markets, LLC. In addition to her advisory role at Berg Capital Markets, LLC, Dr. Hirani currently works as a medical/healthcare industry consultant for NavMed Partners LLC. As a consultant, Dr. Hirani prepares proprietary client focused services including due diligence, valuation analysis, market research, and product research for biotechnology, pharmaceutical, healthcare staffing, healthcare IT and medical device companies, and is also a contributing writer for platforms such as Seeking Alpha and StockViews. Previously, Dr. Hirani worked as a biotechnology equity research analyst producing institutional quality equity research for under-valued and under-followed healthcare, biotechnology and medical device companies. Dr. Hirani’s initiating coverage reports, research reports and articles have been featured on both institutional and retail platforms including Thomson Reuters First Call, Bloomberg, Wall Street Source, Yahoo! Finance, Fidelity.com, and Google Finance. In the past, Dr. Hirani has taught embryology, performed research in the area of optical mammography, and taught English as a Second Language (ESL) classes. Dr. Hirani graduated from Tufts University with a B.S. in Biomedical Engineering and B.S in Biology, and received her Doctor of Medicine (M.D.) degree from St. George’s University School of Medicine. She completed her clinical clerkships primarily through the Barnabas Health System located in the New York Metropolitan area. In her free time, Dr. Hirani enjoys tennis, canvas painting, and volunteering for various non-profit organizations.
I work in NYC and try to put some of my ideas on Seeking Alpha when I can. I usually look at special situations which involves value plays with catalysts. You can also follow me on my blog, which is - http://valuestocks-kedar.blogspot.com
I've been in investment management since 1990, currently as the money manager for Worm Capital. I received my law degree from the University of Oregon in 1984, worked as an accountant for the international accounting firm KPMG, then got involved in investing. I've written over 300 columns for The Financial Times, TheStreet.com, Realmoney.com and SeekingAlpha.com.
The professionals at Eight Diamonds Advisors have on average more than 20 years of experience working in the financial markets. Their backgrounds cover a broad swath of disciplines including M&A, restructuring, forensic accounting, investment management and research analysis.
Arquitos Capital Management is the general partner of a value-oriented hedge fund, Arquitos Capital Partners. Launched in 2012, Arquitos Capital Partners focuses on company-specific situations such as reorganizations, recapitalizations, liquidations, spin-offs, break-ups, rights offerings and other unique circumstances.
Steven Kiel is the president and chief investment officer of Arquitos Capital Management, a Registered Investment Advisory firm he founded in 2009. He is the portfolio manager of Arquitos Capital Partners, a private investment partnership focused on value-oriented holdings.
Steven is a judge advocate in the Army Reserves. He is a veteran of Operation Iraqi Freedom and currently holds the rank of major. Prior to launching Arquitos Capital Management, he was a lawyer in private practice.
He has been quoted in The Wall Street Journal, Bloomberg, MarketWatch, Deal Journal, The Atlantic, USA Today, and other publications. Steven sits on the board of Sitestar (OTCBB:SYTE), a Virginia-based real estate investment company.
Steven is a graduate of George Mason School of Law and Illinois State University, and is a member of the bar in Illinois and Washington, D.C. A Chicago native, he lives with his wife and two golden retrievers in Coronado, CA.
I am the President and Portfolio Manager at Motiwala Capital LLC, a Registered Investment Advisor in the state of Texas. I employ a value oriented investment philosophy. I look for quality companies that have strong balance sheets, produce stable free cashflow and generate above average returns on capital. We purchase at attractive discounts to their intrinsic value.
I started managing separate accounts in 2011. Currently managed $5.4million in assets. Please find presentations, interviews and client letters at www.motiwalacapital.com
Roddy Boyd is an investigative reporter who has worked for Fortune Magazine, the New York Post, The New York Sun and Institutional Investor News. He also founded The Financial Investigator website, www.thefinancialinvestigator.com. I also wrote "Fatal Risk," on the collapse of AIG.
Most recently, he has founded the Southern Investigative Reporting Foundation, www.sirf-online.org.
SIRF is dedicated to providing document-driven investigative reporting on publicly traded companies. Our work is centered on providing accountability and information to the investing public and regulators. We are organized as a tax-exempt organization, are members of the Investigative News Network and gladly adhere to the highest standards of journalistic integrity. We do not invest in any securities, short or long, and do not take payment for our work. No one sees our work prior to publication.